Related Experiment Video

Updated: Aug 24, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Challenges and directions for the pathogen hypothesis of Alzheimer's disease

Stephen R Robinson1, Curtis Dobson, Joseph Lyons

  • 1Department of Psychology, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, Vic. 3800, Australia. stephen.robinson@med.monash.edu.au

Neurobiology of Aging
|June 3, 2004
PubMed

Insights

Investigating infectious agents like Herpes simplex virus type 1 (HSV1) and Chlamydophila pneumoniae (Cp) as potential triggers for Alzheimer's disease (AD) requires more research. Current evidence is limited, highlighting a need for further study into pathogen involvement in AD pathogenesis.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Pathology

Background:

  • Emerging evidence suggests a potential link between pathogen infiltration of the brain and Alzheimer's disease (AD).
  • Specific pathogens, including Herpes simplex virus type 1 (HSV1) and Chlamydophila pneumoniae (Cp), are being investigated for their role in AD.
  • The hypothesis posits that these infections may act as triggers or co-factors in AD development.

Purpose of the Study:

  • To critically review the existing evidence linking brain infections by pathogens to Alzheimer's disease (AD).
  • To identify the limitations and inconsistencies in current research supporting this hypothesis.
  • To outline future research directions for investigating the role of pathogens in AD pathogenesis.

Main Methods:

  • Critical literature review of experimental and epidemiological studies.
  • Analysis of evidence for pathogen presence in AD brains.
  • Evaluation of studies demonstrating pathogen-induced neuropathology and cognitive deficits.

Main Results:

  • Current evidence for pathogen involvement in AD is limited and often inconsistent.
  • There is a notable lack of experimental data showing pathogens causing AD-like neuropathological changes or cognitive deficits.
  • Independent confirmation of Chlamydophila pneumoniae (Cp) in AD brains and evidence of HSV1 proteins or virions are lacking.

Conclusions:

  • The hypothesis that pathogens like HSV1 and Cp contribute to Alzheimer's disease (AD) warrants further rigorous investigation.
  • Significant gaps exist in experimental evidence, particularly regarding pathogen-induced neuropathology and cognitive decline.
  • Future research should focus on epidemiological studies and consider systemic infections as potential contributors to AD pathogenesis.

More Related Videos

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...